Recent News

• 09.15.2025 - IceCure Receives Regulatory Approval in Israel for its Next-Generation XSense™ Cryoablation System for Breast Cancer and Other Indications
• 09.08.2025 - Two New Publications from the Independent THERMAC Trial Featuring IceCure's ProSense® in Breast Cancer Finds 95% of Patients Satisfied with Thermal Ablation; ProSense® Cryoablation Achieves Highest Complete Ablation Rate
• 09.04.2025 - IceCure's ProSense® Substantially Reduces Abdominal Wall Endometriosis Pain with High Procedural Efficacy
• 08.13.2025 - IceCure Reports Financial & Operational Results for the First Half of 2025
• 08.06.2025 - IceCure to Report First Half 2025 Financial and Operating Results on August 13, 2025
• 08.04.2025 - Join IceCure at the 2025 CIRSE Annual Meeting in Barcelona

Recent Filings

• 09.15.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 09.15.2025 - EX-99.1 EX-99.1
• 09.04.2025 - EX-99.1 EX-99.1
• 09.04.2025 - F-3 Registration statement by foreign private issuers
• 09.04.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 09.04.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.20.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.13.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.13.2025 - EX-99.1 EX-99.1
• 08.04.2025 - EFFECT Notice of Effectiveness